News
(3)April 2026
SLDB annual report reviews financial runway and DMD clinical progress
# 🧾 What This Document Is This is Solid Biosciences' **Annual Report to Shareholders (ARS)** for the year 2025. Think of it as the company's comprehensive "year-in-review" newsletter sent directly to its owners. It goes beyond the basic financial numbers to tell the story of their progress, challe
SLDB Seeks Shareholder Approval to Double Authorized Shares
# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for **Solid Biosciences Inc. (SLDB)**. Think of it as the official "agenda packet" for the company's annual shareholder meeting. Its purpose is to give shareholders the information they need to vote on key company matters
Solid Biosciences Inc. — PRE 14A Filing
# 🧾 What This Document Is This is a **PRE 14A** filing, a "Preliminary Proxy Statement." Think of it as a preview of the agenda and information packet for Solid Biosciences' upcoming annual shareholder meeting. The company is giving shareholders the details they need to vote on important issues. It
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.